Key result
Direct oral anticoagulants significantly reduced the risk of any form of post-thrombotic syndrome compared to vitamin K antagonists (OR 0.57; 95% CI 0.48-0.68; P<0.001).
Why the study?
Data regarding the benefits of direct oral anticoagulants compared with vitamin K antagonists in preventing post-thrombotic syndrome after deep vein thrombosis have been inconsistent.
Do direct oral anticoagulants reduce the risk of post-thrombotic syndrome in patients with deep vein thrombosis compared to vitamin K antagonists?
Meta-Analysis (n=3,161)
Do direct oral anticoagulants reduce the risk of post-thrombotic syndrome in patients with deep vein thrombosis compared to vitamin K antagonists?
In patients with deep vein thrombosis, the use of DOACs (particularly rivaroxaban) significantly reduces the risk of developing any and severe post-thrombotic syndrome compared to vitamin K antagonists.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lobastov et al. (2022) conducted a meta-analysis in Deep vein thrombosis (n=3,161). Direct oral anticoagulants vs. Vitamin K antagonists was evaluated on Any form of post-thrombotic syndrome (OR 0.57, 95% CI 0.48-0.68, p=<0.001). Direct oral anticoagulants significantly reduced the risk of any form of post-thrombotic syndrome compared to vitamin K antagonists (OR 0.57; 95% CI 0.48-0.68; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: